Evidence Snapshot

cGMP-specific 3',5'-cyclic phosphodiesterase

CHEMBL1827 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:21Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 12:22 PM KST As of · Sep 14, 2026

ChEMBL ChEMBL 36 CHEMBL1827

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats cGMP-specific 3',5'-cyclic phosphodiesterase as ChEMBL target CHEMBL1827, mapped to UniProt O76074. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

cGMP-specific 3',5'-cyclic phosphodiesterase

SINGLE PROTEIN · Homo sapiens

As of 2026-09-14

ChEMBL target ID

CHEMBL1827

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-14

www.ebi.ac.uk

UniProt accession

O76074

cGMP-specific 3',5'-cyclic phosphodiesterase

UniProt accession via ChEMBL component mapping As of 2026-09-14

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-14

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why cGMP-specific 3',5'-cyclic phosphodiesterase matters

As of 2026-09-14

cGMP-specific 3',5'-cyclic phosphodiesterase is reviewed as cGMP-specific 3',5'-cyclic phosphodiesterase (UniProt O76074); cGMP-specific 3',5'-cyclic phosphodiesterase shows approved-linked disease relevance led by erectile dysfunction. 5 more disease programs remain visible in the same review block.; 5 linked drugs keep this evidence frame grounded.; the current evidence base includes 20 approved drugs, 3669 compounds, and 432 assays, with lead potency reaching pChEMBL 11.0.

Protein context

cGMP-specific 3',5'-cyclic phosphodiesterase

cGMP-specific 3',5'-cyclic phosphodiesterase Sequence length is 875 aa.

Review this target as cGMP-specific 3',5'-cyclic phosphodiesterase, mapped to UniProt O76074. Sequence length is 875 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt O76074 Protein

Disease context

erectile dysfunction

cGMP-specific 3',5'-cyclic phosphodiesterase shows approved-linked disease relevance led by erectile dysfunction. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AVANAFIL, SILDENAFIL CITRATE, TADALAFIL.

Start review with erectile dysfunction because it currently carries approved-linked support. Linked drugs include AVANAFIL, SILDENAFIL CITRATE, TADALAFIL, UDENAFIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 5 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 20 approved drugs, 3669 compounds, and 432 assays for this target. The dominant activity type is IC50. CHEMBL1916483 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL1916483 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine

20 approved pChEMBL 11.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why cGMP-specific 3',5'-cyclic phosphodiesterase matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt O76074, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why erectile dysfunction is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3669

Total Compounds

432

Total Assays

Approved Drugs

IC50: 3538.0, KI: 982.0, EC50: 30.0, KD: 9.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL1916483	11.0	IC50	—
No preferred name CHEMBL1916488	11.0	IC50	—
No preferred name CHEMBL1098465	11.0	IC50	—
No preferred name CHEMBL1916475	10.7	IC50	—
No preferred name CHEMBL1916485	10.7	IC50	—

Approved Drugs

Structure	Compound	First Approval
	AVANAFIL CHEMBL1963681	2011
	VARDENAFIL CHEMBL1520	2003
	VARDENAFIL HYDROCHLORIDE CHEMBL1339	2003
	TADALAFIL CHEMBL779	2002
	SILDENAFIL CHEMBL192	1998
	SILDENAFIL CITRATE CHEMBL1737	1998
	DONEPEZIL CHEMBL502	1996
	MILRINONE CHEMBL189	1987
	DIPYRIDAMOLE CHEMBL932	1961

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:21Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 12:22 PM KST As of · Sep 14, 2026

ChEMBL ChEMBL 36 CHEMBL1827